ornithylaspartate has been researched along with Non-alcoholic Fatty Liver Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, H; Xia, M; Xu, Y; Yang, X | 1 |
| Álvares-da-Silva, MR; Behrens, L; Cerski, CT; de Freitas, LBR; de Souza, VEG; Filippi-Chiela, E; Leonhard, LC; Lima, GJSP; Longo, L; Luchese, E; Pereira, MHM; Pinzon, CE; Uribe-Cruz, C; Zanettini, G | 1 |
| Butterworth, RF; Canbay, A | 1 |
| Canbay, A; Sowa, JP | 1 |
| Chen, SH; Gong, LB; Li, YM; Lu, LG; Luo, HS; Pang, Z; Shi, JP; Tan, SY; Tang, CW; Tian, LY; Xie, Y; Zhang, YL | 1 |
2 review(s) available for ornithylaspartate and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management.
Topics: Age Factors; Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; COVID-19; COVID-19 Drug Treatment; Cytokines; Dipeptides; Gene Expression Regulation; Glucose; Glycyrrhizic Acid; Humans; Hypoxia; Liver; Lung; Non-alcoholic Fatty Liver Disease; Receptors, Virus; SARS-CoV-2; Severity of Illness Index | 2021 |
Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.
Topics: Dipeptides; Glutamine; Glutathione; Humans; Liver; Non-alcoholic Fatty Liver Disease; Protective Agents | 2019 |
1 trial(s) available for ornithylaspartate and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
[Aspartate-ornithine granules in the treatment of nonalcoholic steatohepatitis: a multiple-dose parallel controlled clinical trial].
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Dipeptides; Dose-Response Relationship, Drug; Female; gamma-Glutamyltransferase; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Triglycerides | 2013 |
2 other study(ies) available for ornithylaspartate and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Ornithine Aspartate and Vitamin-E Combination Has Beneficial Effects on Cardiovascular Risk Factors in an Animal Model of Nonalcoholic Fatty Liver Disease in Rats.
Topics: Animals; Cardiovascular Diseases; Dipeptides; Disease Models, Animal; Drug Therapy, Combination; Liver; MicroRNAs; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Risk Factors; Vitamin E | 2022 |
L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease.
Topics: Ammonia; Animals; Antioxidants; Dipeptides; Fatty Liver; Glutamine; Glutathione; Humans; Liver; Non-alcoholic Fatty Liver Disease; Signal Transduction | 2019 |